GSK3B and Parkinson disease: Consequences of GSK-3β activation not only encompass increasing α-synuclein aggregates in vitro PD models (Arciniegas Ruiz and Eldar-Finkelman 2022) but also extend to amplification of mitochondrial apoptosis (King et al. 2001; Linseman et al. 2004).